EGFR and neoplasm: The researchers also elucidated that erlotinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, exerts its antineoplastic effects by curtailing tumor angiogenesis and fortifying existing vasculature, thereby obstructing tumor vascular remodeling.